PDF(Pubmed)
Abstract：
OBJECTIVE: Triple-Negative Breast Cancer (TNBC) is known for its aggressiveness and treatment challenges due to the absence of ER, PR, and HER2 receptors. Our work emphasizes the prognostic value of LCP1 (Lymphocyte cytosolic protein 1), which plays a crucial role in cell processes and immune cell activity, to predict outcomes and guide treatments in TNBC.
METHODS: We explored LCP1 as a potential biomarker in TNBC and investigated the mRNA and protein expression levels of LCP1. We investigated different databases, including GTEX, TCGA, GEO, cBioPortal and Kaplan-Meier Plotter. Immunohistochemistry on TNBC and benign tumor samples was performed to examine LCP1\'s relationship with patient clinical characteristics and macrophage markers. We also assessed survival rates, immune cell infiltration, and drug sensitivity related to LCP1 using various bioinformatics tools.
RESULTS: The results indicated that LCP1 expression was higher in TNBC tissues compared to adjacent normal tissues. However, high expression of LCP1 was significantly associated with favorable survival outcomes in patients with TNBC. Enrichment analysis revealed that genes co-expressed with LCP1 were significantly enriched in various immune processes. LCP1 showed a positive correlation with the infiltration of resting dendritic cells, M1 macrophages, and memory CD4 T cells, and a negative correlation with M2 macrophages. Further analysis suggested a link between high levels of LCP1 and increased survival outcomes in cancer patients receiving immunotherapy.
CONCLUSIONS: LCP1 may serve as a potential diagnostic and prognostic biomarker for TNBC, which was closely associated with immune cell infiltration, particularly M1 and M2 macrophages. Our findings may provide valuable insights into immunotherapeutic strategies for TNBC patients.
METHODS: We explored LCP1 as a potential biomarker in TNBC and investigated the mRNA and protein expression levels of LCP1. We investigated different databases, including GTEX, TCGA, GEO, cBioPortal and Kaplan-Meier Plotter. Immunohistochemistry on TNBC and benign tumor samples was performed to examine LCP1\'s relationship with patient clinical characteristics and macrophage markers. We also assessed survival rates, immune cell infiltration, and drug sensitivity related to LCP1 using various bioinformatics tools.
RESULTS: The results indicated that LCP1 expression was higher in TNBC tissues compared to adjacent normal tissues. However, high expression of LCP1 was significantly associated with favorable survival outcomes in patients with TNBC. Enrichment analysis revealed that genes co-expressed with LCP1 were significantly enriched in various immune processes. LCP1 showed a positive correlation with the infiltration of resting dendritic cells, M1 macrophages, and memory CD4 T cells, and a negative correlation with M2 macrophages. Further analysis suggested a link between high levels of LCP1 and increased survival outcomes in cancer patients receiving immunotherapy.
CONCLUSIONS: LCP1 may serve as a potential diagnostic and prognostic biomarker for TNBC, which was closely associated with immune cell infiltration, particularly M1 and M2 macrophages. Our findings may provide valuable insights into immunotherapeutic strategies for TNBC patients.
摘要：
目的：三阴性乳腺癌（TNBC）因缺乏ER而具有侵袭性和治疗挑战，PR,和HER2受体。我们的工作强调LCP1（淋巴细胞胞浆蛋白1）的预后价值，在细胞过程和免疫细胞活动中起着至关重要的作用，预测结果并指导TNBC的治疗。
方法：我们探索了LCP1作为TNBC的潜在生物标志物，并研究了LCP1的mRNA和蛋白质表达水平。我们调查了不同的数据库,包括GTEX,TCGA,GEO,cBioPortal和Kaplan-Meier绘图仪。对TNBC和良性肿瘤样本进行免疫组织化学检查，以检查LCP1与患者临床特征和巨噬细胞标记的关系。我们还评估了生存率，免疫细胞浸润，以及使用各种生物信息学工具与LCP1相关的药物敏感性。
结果：结果表明，与邻近的正常组织相比，TNBC组织中LCP1的表达更高。然而,LCP1的高表达与TNBC患者的良好生存结局显著相关.富集分析显示与LCP1共表达的基因在各种免疫过程中显著富集。LCP1与静息树突状细胞浸润呈正相关,M1巨噬细胞，和记忆CD4T细胞，与M2巨噬细胞呈负相关。进一步的分析表明，高水平的LCP1与接受免疫治疗的癌症患者的生存结果增加之间存在联系。
结论：LCP1可作为TNBC的潜在诊断和预后生物标志物，这与免疫细胞浸润密切相关，特别是M1和M2巨噬细胞。我们的发现可能为TNBC患者的免疫治疗策略提供有价值的见解。
方法：我们探索了LCP1作为TNBC的潜在生物标志物，并研究了LCP1的mRNA和蛋白质表达水平。我们调查了不同的数据库,包括GTEX,TCGA,GEO,cBioPortal和Kaplan-Meier绘图仪。对TNBC和良性肿瘤样本进行免疫组织化学检查，以检查LCP1与患者临床特征和巨噬细胞标记的关系。我们还评估了生存率，免疫细胞浸润，以及使用各种生物信息学工具与LCP1相关的药物敏感性。
结果：结果表明，与邻近的正常组织相比，TNBC组织中LCP1的表达更高。然而,LCP1的高表达与TNBC患者的良好生存结局显著相关.富集分析显示与LCP1共表达的基因在各种免疫过程中显著富集。LCP1与静息树突状细胞浸润呈正相关,M1巨噬细胞，和记忆CD4T细胞，与M2巨噬细胞呈负相关。进一步的分析表明，高水平的LCP1与接受免疫治疗的癌症患者的生存结果增加之间存在联系。
结论：LCP1可作为TNBC的潜在诊断和预后生物标志物，这与免疫细胞浸润密切相关，特别是M1和M2巨噬细胞。我们的发现可能为TNBC患者的免疫治疗策略提供有价值的见解。
